|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XC32
|
|
gptkbp:brand
|
gptkb:Tecentriq
|
|
gptkbp:CASNumber
|
gptkb:1448221-59-6
|
|
gptkbp:chemicalFormula
|
C6528H10008N1732O2036S42
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Roche
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
atezolizumab
|
|
gptkbp:indication
|
gptkb:triple-negative_breast_cancer
Small Cell Lung Cancer
hepatocellular carcinoma
locally advanced non-small cell lung cancer
metastatic non-small cell lung cancer
locally advanced urothelial carcinoma
metastatic urothelial carcinoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
IgG1 monoclonal antibody
|
|
gptkbp:mechanismOfAction
|
PD-L1 inhibitor
|
|
gptkbp:molecularWeight
|
146000 Da
|
|
gptkbp:origin
|
humanized antibody
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034s027lbl.pdf
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
rash
immune-related adverse events
|
|
gptkbp:target
|
gptkb:programmed_death-ligand_1
|
|
gptkbp:UNII
|
6X9OC3H4II
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma
gptkb:cancer
gptkb:triple-negative_breast_cancer
|
|
gptkbp:bfsParent
|
gptkb:Small_cell_lung_cancer
gptkb:PD1
gptkb:locally_advanced_or_metastatic_urothelial_carcinoma
gptkb:programmed_death-ligand_1
gptkb:programmed_death-ligand_1_(PD-L1)
gptkb:Tecentriq
gptkb:IMpower150
gptkb:NSCLC
gptkb:PD-L1_inhibitors
|
|
gptkbp:bfsLayer
|
7
|